Comparison of Cardiac Resynchronisation Therapy (CRT) Response Using High Frequency (HF) - ECG or Q-LV Guided Optimisation for Left Ventricular, Pacing Site.
Study Details
Study Description
Brief Summary
The research aims to compare the response of Cardiac Resynchronisation Therapy (CRT) using HF ECG guided or the conventional method of Q-LV measurement guided optimisation for left ventricular, pacing site.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The study aims to demonstrate that left ventricular (LV) pacing site optimisation using high frequency (HF) ECG improves LV reverse remodeling response to Cardiac Resynchronization Therapy (CRT), compared with Q-LV (Q-wave on the surface ECG to LV Electrogram) measurement after 6 months of treatment.
Participants will be implanted with a Cardiac Resynchronisation Therapy device with either pacemaker or defibrillator function.
The study is a single-Centre, randomized, prospective trial. One hundred and eighty participants will be assigned to either the treatment (HF-ECG guided LV pacing site optimisation) or control (Q-LV guided LV pacing site optimisation) arm, employing a 1:1 randomization. The participants will be followed up for a period of 6 months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: HF-ECG guided LV pacing site optimisation Participants will have the left ventricular pacing site programmed based on the results of HF-ECG mapping to locate the area of latest activation and best pattern of paced resynchronisation. |
Other: High Frequency ECG Mapping
A high frequency ECG map will be performed to assess the optimum left ventricular pacing site.
|
| Active Comparator: Q-LV guided LV pacing site optimisation Participants will have the left ventricular pacing site programmed based on the results of Q-LV measurement to locate the area of latest activation. This is the standard of care method for pacing site optimisation. |
Other: Q-LV Measurement
Measurement of Q wave on 12 lead ECG to LV stimulus to assess optimum left ventricular pacing site.
|
Outcome Measures
Primary Outcome Measures
- Left Ventricular Reverse Remodelling [6 months]
Absolute difference in left ventricular end systolic volume greater than or equal to 10%
Secondary Outcome Measures
- Change in NYHA Class [6 months]
- Change in quality of life score [6 months]
Assessment through Minnesota Living with Heart Failure Questionnaire
- Change in left ventricular ejection fraction [6 months]
Improved left ventricular ejection fraction
- Reduction in QRS duration [6 months]
QRS duration measured on 12 lead ECG
Eligibility Criteria
Criteria
Inclusion Criteria:
-
• Eligible for implantation of a CRT-D device according to published relevant ESC and CCS guidelines;
-
In sinus rhythm;
-
NYHA class II, III or IV
-
Have reviewed, signed and dated an informed consent.
-
Age 18
Exclusion Criteria:
-
- Previous implant with a pacemaker, an ICD or a CRT device. (except upgrade from single chamber ICD with a fully functional defibrillation lead) not under recall or surveillance); 2. Persistent atrial arrhythmias (or cardioversion for atrial fibrillation) within the past month; 3. Ventricular tachyarrhythmia of transient or reversible causes such as acute myocardial infarction (MI), digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment; 4. Incessant ventricular tachyarrhythmia; 5. Unstable angina, or acute MI, Coronary Artery Bypass-Grafting (CABG), or Percutaneous Coronary Intervention (PCI) within the past 4 weeks; 6. Correctable valvular disease that is the primary cause of heart failure; 7. Indication for valve repair or replacement; 8. Recent Cerebro-Vascular Accident (CVA) or Transient Ischemic Attack (TIA) (within the previous 3 months); 9. On transplant waiting list; 10. Previous heart transplant; 11. Already included in another clinical study that could confound the results of this study; 12. Life expectancy less than 1 year; 13. Inability to understand the purpose of the study; 14. Unavailability for scheduled follow-up or refusal to cooperate; 15. Age of less than 18 years; 16. Pregnancy; 17. Drug addiction or abuse; 18. Under guardianship.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University Hospitals Birmingham | Birmingham | West Midlands | United Kingdom | B15 2GW |
Sponsors and Collaborators
- University Hospital Birmingham
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RRK7831